IceCure Medical Ltd. Ordinary Shares (ICCM) — Analysis Summary
IceCure Medical Ltd. Ordinary Shares (ICCM) has a market cap of $7.85M with year-over-year revenue growth of +2.7%. Net margin stands at -445.6%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed +2.7% year-over-year
- Net margin of -445.6%
- P/E ratio of -0.5
Compared with its sector, ICCM posted revenue growth of +2.7% and trades at a P/E of -0.5.
IceCure Medical Ltd. Ordinary Shares (ICCM)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -446.7% — severe operating losses
Net margin at -445.6% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Employees
66
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.